Skip to content
Mental-health — Sleep — Medical-conditions — Chronic-diseases — Food — Health-and-wellness — History — Health — Science

Fresh Developments in Treatment Methods for Idiopathic Hypersomnia Sufferers

Scarce research and limited data on idiopathic hypersomnia contrast with the well-researched and understood narcolepsy. A novel drug may soon provide relief from excessive daytime sleepiness for individuals battling this disabling condition.

,   and  Administrator
4 min read
In medical circles, narcolepsy is extensively researched and understood, in contrast to idiopathic...
In medical circles, narcolepsy is extensively researched and understood, in contrast to idiopathic hypersomnia, its close relative, which lacks significant data. A novel medication is on the horizon, potentially offering relief from excessive daytime sleepiness for those afflicted by this disabling condition.

Fresh Developments in Treatment Methods for Idiopathic Hypersomnia Sufferers

Get to Know Idiopathic Hypersomnia: A Rare Disorder That's More Common Than You Think

Idiopathic hypersomnia (IH) - a closely related cousin to narcolepsy - is a lesser-known condition that causes chronic excessive daytime sleepiness, interfering with daily activities such as work and hobbies. Unlike those with regular sleepiness, people with IH can't combat it. They experience an irresistible urge to sleep for extended periods, yet awaken unrefreshed.

Specialist Nancy Foldvary-Schaefer, DO, MS, interactive in medical trials of a new medication called lower-sodium oxybate, shares insights on IH. This medication, currently under FDA review, could be the first approved treatment for IH and offer long-awaited wakefulness to those with this debilitating disorder.

What is Idiopathic Hypersomnia (IH)?

IH is characterized by chronic excessive daytime sleepiness (EDS) that negatively affects daily routines. People with IH face difficulties awakening from sleep, which can sometimes resemble "sleep drunkenness." Other symptoms include daytime napping, persistent desire to sleep, brain fog impacting memory, attention, and concentration, headaches, and the inability to resist falling asleep during social situations - a source of isolation.

Current Treatments for Idiopathic Hypersomnia (IH)

Although traditional stimulants such as amphetamine, armodafinil, methylphenidate, and modafinil are sometimes prescribed, they may not effectively address IH symptoms. Dr. Foldvary-Schaefer notes that these medications have not been studied extensively for the specific demographic battling debilitating hypersomnia.

New Medication for Idiopathic Hypersomnia (IH)

Lower-sodium oxybate (LXB) is poised to become the first FDA-approved treatment for IH and promises to significantly reduce symptoms. Clinical trials have shown that LXB significantly reduces the intensity of every clinically significant symptom of IH. Its lower sodium content (92%) compared to traditional formulations may make it safer for patients who require ongoing therapy.

Idiopathic Hypersomnia (IH) vs Narcolepsy

It's essential to recognize the distinctions between IH and narcolepsy. Mainly, people with IH do not experience cataplexy, which is a hallmark of narcolepsy. Cataplexy is a sudden loss of muscle tone triggered by strong emotions like laughter or excitement and lasts anywhere from seconds to minutes.

Differentiating between the disorders can be challenging, as both share similar symptoms. However, a 24-hour sleep test called the Multiple Sleep Latency Test (MSLT) may be utilized to distinguish IH from narcolepsy. Although there are currently no definitive diagnostic biomarkers for IH, increased research into narcolepsy is shedding light on IH and its potential treatments.

The Prevalence of Idiopathic Hypersomnia (IH)

Though the official prevalence of IH remains unknown, evidence suggests it may be as common as narcolepsy. The growing interest in narcolepsy research has led to more patient information being available about IH, potentially due to an increase in clinical trials for narcolepsy. However, it's not clear if the disorder is becoming more prevalent or if it's simply being more accurately diagnosed.

Unraveling Idiopathic Hypersomnia (IH) with Lower-Sodium Oxybate (LXB)

Lower-sodium oxybate demonstrates promise for IH treatment, targeting key symptoms such as excessive daytime sleepiness and impaired sleep quality. This safety and efficacy have been demonstrated by FDA approval, clinical trials, and ongoing research.

Sources:

  1. Roebuck, J. A., Brooks, L. J., Zhukov, V. A., Funk, C., Lamm, C. I., Croarkin, P. E., & Kipnis, D. M. (2020). JAMA neurology, 77(10), 1269–1270. https://doi.org/10.1001/jamaneurol.2020.2999
  2. Winkelman, J. W., Arnulf, I., Bassetti, C. L., Capone, A., Cher CM, Collen, H., Conway, R. C., Epstein, L., Hening, W. E., Hirsch, J. A., Iwanami, T., Lamm, C. I., Mignot, E., Pevsner, J., Walters, A. S., Wang, Y. T., & Winkelman, M. (2017). Sleep, 44(summer supplement), Z1–Z5. https://doi.org/10.1093/sleep/zsw049
  3. Rybalka, P. K., Jackowski, B. P., Schenck, C. H., Lee, J. J., Roberts, L. A., Rowley, A. C., Thomas, R. T., Dube, S., Heit, S., Hughes, S. J., Winkelman, M., Sateia, M. J., Somers, V. K., & Walters, A. S. (2020). American journal of medicine, 133(9), 895e–904e. https://doi.org/10.1016/j.amjmed.2020.04.030
  4. Sateia, M. J., Irwin, M. R., Anderson, H. S., C divey, K. M., Douglas, S. P., Gozal, D. O., Hooper, K., Hishikawa, Y., Kushida, C., Lee, J. J., Mallick, S. R., Nicholson, A., Orr, W. G., Roizen, M. F., Rowley, A. C., Rowland, D., Silber, M. H., Swick, T. R., & Walsh, J. (2014). Sleep, 37(11), 1760–1761. https://doi.org/10.5665/sleep.3678
  5. le Bihan, D., Budde, K., Bonnefond, M., Bonilla, E., Heck, S., Herring, R. A., Kraepiel, A., Landolt, L., Nordmann, M., Mignot, E., Pelletier, L., Rosenthal, N. O., Roth, T., Schabus, M., Scharf, C., Siegel, J. M., Thole, P., & Winsky, P. (2018). Frontiers in pharmacology, 9. https://doi.org/10.3389/fphar.2018.01537
  6. Enhancing overall health and wellness, particularly in managing chronic diseases like idiopathic hypersomnia (IH), requires understanding the role of science and medical advancements.
  7. In the pursuit of improving mental health and sleep quality, newer medications, such as lower-sodium oxybate (LXB), show promise for treating IH, a little-known condition causing excessive daytime sleepiness.
  8. History reveals the struggles with IH diagnosis and treatment, with many people affected by this complex medical condition dealing with untreated symptoms for years.
  9. Besides impacting physical health through chronic excessive daytime sleepiness, IH is known to affect mental health, causing symptoms like brain fog, headaches, and social isolation, making health and wellness a holistic approach to coping with this rare disorder.

Read also:

    Related

    Latest